<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086215</url>
  </required_header>
  <id_info>
    <org_study_id>PEARLII</org_study_id>
    <nct_id>NCT01086215</nct_id>
  </id_info>
  <brief_title>Registry of AngioJet Use in the Peripheral Vascular System</brief_title>
  <acronym>PEARLII</acronym>
  <official_title>PEARL II: PEripheral Use of AngioJet® Rheolytic Thrombectomy With a Variety of Catheter Lengths</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Registry involves the collection of information for research and educational purposes
      only on the use of AngioJet in the peripheral vascular system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PEARL II Registry is a prospective, multi-center, observational registry including 500
      patients who meet eligibility from up to 50 sites worldwide. Patient participation will be 12
      months including post procedure follow-up contact at 3, 6 and 12 months. The study duration
      is estimated at 36 months.

      A patient's treatment is determined by the treating physician based on the clinical situation
      and local practices. In contrast to a randomized, controlled trial, there are no pre-defined
      experimental interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Degree of Occlusion From Baseline to Final Angiogram/Venogram.</measure>
    <time_frame>Day 1</time_frame>
    <description>From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms/venograms, each vessel was assigned a value by the treating physician.
complete occlusion (&gt;90% occlusion);
substantial occlusion (50-90% occlusion OR &lt;50% occlusion and &gt;3cm in length);
partial occlusion (&lt;50% occlusion AND &lt;3cm in length)
patent (without visable thrombus or occlusion) The levels of change (improvement) were calculated by subtracting the baseline assigned angiographic/venographic value from the final value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rethrombosis</measure>
    <time_frame>3 Month , 6 Month and 12 Month Follow Up</time_frame>
    <description>The number of patients affected by rethrombosis of the treated vessels (first episode) throughout a 12 Month Follow-Up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concomitant Treatments Used With the AngioJet® System</measure>
    <time_frame>Day 1</time_frame>
    <description>The # of patients exposed to each treatment option at least once in the given thrombotic condition during the Index Procedure</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">500</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Embolism and Thrombosis</condition>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Limb Ischemia</arm_group_label>
    <description>Patients presenting with limb ischemia for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep Vein Thrombosis</arm_group_label>
    <description>Patients presenting with deep vein thrombosis for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemodialysis Access</arm_group_label>
    <description>Patients presenting with thrombosed hemodialysis access for treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Thrombotic Conditions</arm_group_label>
    <description>Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community population
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been treated in the peripheral vascular system with any of the AngioJet
             System catheters.

          -  Patient has provided appropriate consent/authorization per the site's institutional
             policy and procedure.

        Exclusion Criteria:

          -  Patient has previously been enrolled in either the PEARL Registry or the PEARL II
             Registry in the last 12months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence Blitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chilton Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Lookstein, MD</last_name>
    <role>Study Director</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali Amin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Reading Hospital &amp; Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Heart, PLLC</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John C. Lincoln Deer Valley Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida- College of Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Hospital</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Recknor PC</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Arnett</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Health</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terrebonne General Medical Center</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Medical Center of Acadiana</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chilton Memorial Hospital</name>
      <address>
        <city>Pompton Plains</city>
        <state>New Jersey</state>
        <zip>07444</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grant Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Toledo Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's Hospital &amp; Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Reading Hospital &amp; Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Heart Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Valley Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winchester Medical Center</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Area Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Regional Health Authority</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Naples</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of CV Diseases</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>March 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2010</study_first_posted>
  <results_first_submitted>October 29, 2014</results_first_submitted>
  <results_first_submitted_qc>October 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2014</results_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Embolism and Thrombosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients presenting at a participating site who were clinically indicated for a peripheral interventional (arterial, venous or hemodialysis access) procedure with the AngioJet Thrombectomy System were offered the opportuntity to participate. Patients were recruited from January 2010 thru June 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Limb Ischemia</title>
          <description>Patients presenting with limb ischemia for treatment</description>
        </group>
        <group group_id="P2">
          <title>Deep Vein Thrombosis</title>
          <description>Patients presenting with deep vein thrombosis for treatment</description>
        </group>
        <group group_id="P3">
          <title>Hemodialysis Access</title>
          <description>Patients presenting with thrombosed hemodialysis access for treatment</description>
        </group>
        <group group_id="P4">
          <title>Other Thrombotic Conditions</title>
          <description>Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Month Follow Up</title>
              <participants_list>
                <participants group_id="P1" count="201">7 LTF; 4 Deaths</participants>
                <participants group_id="P2" count="187">10 LTF; 4 Deaths</participants>
                <participants group_id="P3" count="64">5 LTF; 4 Deaths</participants>
                <participants group_id="P4" count="13">1 LTF; 0 Deaths</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Month Follow Up</title>
              <participants_list>
                <participants group_id="P1" count="192">5 LTF; 4 Deaths</participants>
                <participants group_id="P2" count="172">13 LTF; 2 Deaths</participants>
                <participants group_id="P3" count="60">4 LTF; 0 Deaths</participants>
                <participants group_id="P4" count="12">1 LTF; 0 Deaths</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Month Follow Up</title>
              <participants_list>
                <participants group_id="P1" count="176">10 LTF; 6 Deaths</participants>
                <participants group_id="P2" count="154">16 LTF; 2 Deaths</participants>
                <participants group_id="P3" count="47">9 LTF; 4 Deaths</participants>
                <participants group_id="P4" count="11">0 LTF; 1 Death</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="154"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Descriptive Analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Limb Ischemia</title>
          <description>Patients presenting with limb ischemia for treatment</description>
        </group>
        <group group_id="B2">
          <title>Deep Vein Thrombosis</title>
          <description>Patients presenting with deep vein thrombosis for treatment</description>
        </group>
        <group group_id="B3">
          <title>Hemodialysis Access</title>
          <description>Patients presenting with thrombosed hemodialysis access for treatment</description>
        </group>
        <group group_id="B4">
          <title>Other Thrombotic Conditions</title>
          <description>Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="11.59"/>
                    <measurement group_id="B2" value="51.3" spread="16.37"/>
                    <measurement group_id="B3" value="61.6" spread="13.94"/>
                    <measurement group_id="B4" value="56.5" spread="12.07"/>
                    <measurement group_id="B5" value="58.1" spread="15.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Degree of Occlusion From Baseline to Final Angiogram/Venogram.</title>
        <description>From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms/venograms, each vessel was assigned a value by the treating physician.
complete occlusion (&gt;90% occlusion);
substantial occlusion (50-90% occlusion OR &lt;50% occlusion and &gt;3cm in length);
partial occlusion (&lt;50% occlusion AND &lt;3cm in length)
patent (without visable thrombus or occlusion) The levels of change (improvement) were calculated by subtracting the baseline assigned angiographic/venographic value from the final value.</description>
        <time_frame>Day 1</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Limb Ischemia</title>
            <description>Patients presenting with limb ischemia for treatment</description>
          </group>
          <group group_id="O2">
            <title>Deep Vein Thrombosis</title>
            <description>Patients presenting with deep vein thrombosis for treatment</description>
          </group>
          <group group_id="O3">
            <title>Hemodialysis Access</title>
            <description>Patients presenting with thrombosed hemodialysis access for treatment</description>
          </group>
          <group group_id="O4">
            <title>Other Thrombotic Conditions</title>
            <description>Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Degree of Occlusion From Baseline to Final Angiogram/Venogram.</title>
          <description>From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms/venograms, each vessel was assigned a value by the treating physician.
complete occlusion (&gt;90% occlusion);
substantial occlusion (50-90% occlusion OR &lt;50% occlusion and &gt;3cm in length);
partial occlusion (&lt;50% occlusion AND &lt;3cm in length)
patent (without visable thrombus or occlusion) The levels of change (improvement) were calculated by subtracting the baseline assigned angiographic/venographic value from the final value.</description>
          <population>Intention to Treat (ITT)</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.03"/>
                    <measurement group_id="O2" value="1.33" spread="0.03"/>
                    <measurement group_id="O3" value="1.36" spread="0.06"/>
                    <measurement group_id="O4" value="1.80" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="0.04"/>
                    <measurement group_id="O2" value="3.73" spread="0.03"/>
                    <measurement group_id="O3" value="3.87" spread="0.04"/>
                    <measurement group_id="O4" value="3.75" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Levels of Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="0.05"/>
                    <measurement group_id="O2" value="2.40" spread="0.04"/>
                    <measurement group_id="O3" value="2.50" spread="0.07"/>
                    <measurement group_id="O4" value="1.95" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Alternative hypothesis is change in occlusion &gt;0</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Alternative hypothesis is change in occlusion &gt;0</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Alternative hypothesis is change in occlusion &gt;0</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Alternative hypothesis is change in occlusion &gt;0</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rethrombosis</title>
        <description>The number of patients affected by rethrombosis of the treated vessels (first episode) throughout a 12 Month Follow-Up.</description>
        <time_frame>3 Month , 6 Month and 12 Month Follow Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Limb Ischemia</title>
            <description>Patients presenting with limb ischemia for treatment</description>
          </group>
          <group group_id="O2">
            <title>Deep Vein Thrombosis</title>
            <description>Patients presenting with deep vein thrombosis for treatment</description>
          </group>
          <group group_id="O3">
            <title>Hemodialysis Access</title>
            <description>Patients presenting with thrombosed hemodialysis access for treatment</description>
          </group>
          <group group_id="O4">
            <title>Other Thrombotic Conditions</title>
            <description>Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Rethrombosis</title>
          <description>The number of patients affected by rethrombosis of the treated vessels (first episode) throughout a 12 Month Follow-Up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 Month Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concomitant Treatments Used With the AngioJet® System</title>
        <description>The # of patients exposed to each treatment option at least once in the given thrombotic condition during the Index Procedure</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Limb Ischemia</title>
            <description>Patients presenting with limb ischemia for treatment</description>
          </group>
          <group group_id="O2">
            <title>Deep Vein Thrombosis</title>
            <description>Patients presenting with deep vein thrombosis for treatment</description>
          </group>
          <group group_id="O3">
            <title>Hemodialysis Access</title>
            <description>Patients presenting with thrombosed hemodialysis access for treatment</description>
          </group>
          <group group_id="O4">
            <title>Other Thrombotic Conditions</title>
            <description>Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Concomitant Treatments Used With the AngioJet® System</title>
          <description>The # of patients exposed to each treatment option at least once in the given thrombotic condition during the Index Procedure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AngioJet Thrombectomy without Lytic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AngioJet Thrombectomy + Lytic Delivery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Balloon Angioplasty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stent Placement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Catheter Directed Thrombolysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atherectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Filter Placement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non AngioJet Thrombectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Index Procedure thru 12 Month Follow Up</time_frame>
      <desc>Events that were related to the initial Index Procedure and/or AngioJet</desc>
      <group_list>
        <group group_id="E1">
          <title>Limb Ischemia</title>
          <description>Patients presenting with limb ischemia for treatment</description>
        </group>
        <group group_id="E2">
          <title>Deep Vein Thrombosis</title>
          <description>Patients presenting with deep vein thrombosis for treatment</description>
        </group>
        <group group_id="E3">
          <title>Hemodialysis Access</title>
          <description>Patients presenting with thrombosed hemodialysis access for treatment</description>
        </group>
        <group group_id="E4">
          <title>Other Thrombotic Conditions</title>
          <description>Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bleeding Requiring Transfusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>DeeAnn Tinjum</name_or_title>
      <organization>Boston Scientific Corporation</organization>
      <phone>763-450-8707</phone>
      <email>deeann.tinjum@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

